Collaborations

Sanford-Burnham Medical Research Institute (Sanford-Burnham) and Daiichi Sankyo Co., Ltd. (Daiichi Sankyo) today announced they have entered into a three-year comprehensive alliance to develop first-in-class therapeutics for the treatment of cardiovascular-metabolic diseases. The collaboration is built on an open-innovation model to bridge the gap between target discovery and pre-clinical drug development.

As research funding from the National Institutes of Health and other federal agencies shrinks, cooperation among the University of Illinois at Chicago (UIC), Northwestern University and the University of Chicago is expanding.

On May 9, the Global Medical Excellence Cluster (GMEC) announced a five-year collaborative agreement with Pfizer Inc. that provides a framework for the research and development of new and innovative medicines for rare diseases.














